Home / Health News / Stempeucel for Buerger's Disease Receives Limited Approval from Drug Controller of India

Stempeucel for Buerger's Disease Receives Limited Approval from Drug Controller of India

An efficient treatment for one of probably the most devastating illness might be within the playing cards because the Drug Controller of India (DGCI) has granted restricted approval for production and advertising and marketing the primary stem cellular treatment for the remedy of Buerger’s illness.

Stempeucel for Buerger’s Disease Receives Limited Approval from Drug Controller of India


Buerger’s illness is an extraordinary life-threatening illness affecting the arteries and veins within the legs. The blood vessels may turn out to be infected and get blocked through small block clots, resulting in diminished blood go with the flow and amputations.

‘Drug Controller of India has granted restricted approval for the primary stem cellular treatment “stempeucel” to regard Buerger’s illness, an extraordinary illness affecting 1,000,000 in India.

There is recently no treatment for this illness apart from bone marrow transplant really useful optionally. The illness impacts about 1,000,000 in India.

A Bangalore-based startup corporate, Stempeutics have advanced a healing product referred to as as “Stempeucel” for this uncommon illness. This remedy can give a boost to the frame to revive blood go with the flow in ischemic tissue through lowering irritation and bettering  new blood vessel formation within the peculiar tissue.

BN Manohar, CEO Stempeutics stated, “We are the first company in India to achieve such approval. It took almost nine years to develop Stempeucel for the treatment of Buerger’s Disease. European Medicines Agency has classified Stempeucel as an Advanced Therapeutic Medicinal Product (ATMP) and designated it as an Orphan Drug (ODD) for the treatment of Buerger’s Disease. Our goal is to globalize Stempeucel for Buerger’s Disease, and the market size is approximately $1.5 billion worldwide”.

Stempeutics Research is a three way partnership between drug maker Cipla and Manipal Group and the corporate is focussed on getting complete approval for their stem cellular treatment through 2018. It is offered for 1.five lakh in India.

He added, “This is a historic step and has opened the gate for stem cell therapy in India. We have now got only limited approval which means we can use it in only a specific number of patients. They have limited it to 200 patients. We have to submit the data of these 200 people to the government and prove that the drugs are safe in terms of efficacy and safety. They have also given us a limit on how much we can charge these patients which is not beyond Rs 1.5 lakh per patient. A single dose is enough. We have to complete it in two years after which we will get a full marketing authorisation and this can be fully distributed to all patients.”

Source: Medindia

About Aadam

Check Also

hepatitis c drug sofosbuvir 300x165 - India Grants Patent for Gilead's Hepatitis C Drug

India Grants Patent for Gilead's Hepatitis C Drug

US pharmaceutical massive Gilead has acquired a patent for its Hepatitis C drug from India. …

Leave a Reply

Your email address will not be published. Required fields are marked *